Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
about
Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidatesThe O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunityMutations in ampG and lytic transglycosylase genes affect the net release of peptidoglycan monomers from Vibrio fischeriAttenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm.A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challengeT- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis.Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in miceExpression of BfrH, a putative siderophore receptor of Bordetella bronchiseptica, is regulated by iron, Fur1, and the extracellular function sigma factor EcfI.Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection.Live attenuated B. pertussis BPZE1 rescues the immune functions of Respiratory Syncytial virus infected human dendritic cells by promoting Th1/Th17 responsesCross-species protection mediated by a Bordetella bronchiseptica strain lacking antigenic homologs present in acellular pertussis vaccines.Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice.Molecular signatures of the evolving immune response in mice following a Bordetella pertussis infection.Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccineTesting the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countriesResurgence of pertussis calls for re-evaluation of pertussis animal models.Pertussis re-emergence in the post-vaccination eraImmunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.Resident microbiota affect Bordetella pertussis infectious dose and host specificity.Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens.Blood-stage immunity to Plasmodium chabaudi malaria following chemoprophylaxis and sporozoite immunizationUse of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccineImmunological Signatures after Bordetella pertussis Infection Demonstrate Importance of Pulmonary Innate Immune CellsContribution of pertussis toxin to the pathogenesis of pertussis diseaseStrategies and new developments to control pertussis, an actual health problemNeedle-free vaccine delivery.Development of improved pertussis vaccine.The Bordetella pertussis type III secretion system tip complex protein Bsp22 is not a protective antigen and fails to elicit serum antibody responses during infection of humans and miceFactors contributing to pertussis resurgence.Mucosal vaccination against bacterial respiratory infections.Safety and efficacy of neonatal vaccination.A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.An improved whole cell pertussis vaccine with reduced content of endotoxin.Meta-Analysis of Pulmonary Transcriptomes from Differently Primed Mice Identifies Molecular Signatures to Differentiate Immune Responses following Bordetella pertussis Challenge.Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism.Pertussis: a matter of immune modulation.Review of diphtheria, tetanus and pertussis vaccines in clinical development.The ins and outs of pertussis toxin.
P2860
Q24657870-258E1F9C-211A-4756-93B3-F589E8854C21Q24672570-DBB11FA8-6FF4-40D1-A300-AF186ED02E0AQ28755149-97FC7A72-7E9B-440B-B013-F8EA9912D729Q30388854-516BEC17-F401-4F5C-A671-3513A1B83B3AQ33360151-F9A4AE31-A87A-4D35-BAC6-42A5CC6E7AF1Q33564283-158D8BF2-CF14-491B-B349-96A09E460D78Q33594345-E9DA00A7-9818-413F-BBF2-60A1F2181975Q33675978-F0BB07AA-0937-457E-84B0-674E6A19260CQ33725151-A36AF4E3-D975-4388-AE2E-18194B58A8D7Q33738499-3C8E21E4-437E-4E1A-903B-CCC2F18E9DDCQ33812212-FB86F97B-9FEB-4F09-8F6C-800CF4E6B776Q33825964-89C52006-EE76-4529-8A0F-61E53050CF85Q34028638-57FBED53-F516-4BFE-97C3-E31165CB9634Q34066406-98EA7CE0-3A93-4EF5-A9F0-BEB6252271B1Q34260834-4DEAD8BF-4EB6-4297-9804-553E2619D2B1Q34276739-27D18DBE-2618-466B-BD1F-75509B0E9E40Q34311615-DD9DF390-CC90-496E-9DE2-02FB1CF28D4AQ34636630-3409A679-1D3B-488C-8F09-928214214C0BQ34650849-8FB9F599-5B47-4CE3-A54C-B62DE6A6912EQ34738678-984F8AEC-D27B-4081-90AB-B18987D241B3Q35042275-A139474B-64A8-4660-9682-204227E9972AQ35066267-14C4B830-3735-4374-A92F-C9CF5F34C98AQ35211003-8FDCC022-029A-4A0D-A1AC-2284003CFF2DQ35913617-D20561E5-0B63-4B14-BF56-D22365C59A01Q36155214-289738D2-27A3-4723-B518-A9FCC3B8F1B0Q36226458-BBC0719D-F9EF-48FF-9791-67523C51A748Q36226470-507BEB0D-01F5-41C5-A448-68322BCEED8CQ36945838-2C7E2299-AE57-4282-84AA-A84424138161Q36978320-3D29B297-262E-46A0-BE2D-42CBC063A069Q37036069-A603BDEB-103E-4264-8FCA-24DBC87A51D2Q37174125-7810D83F-0677-4D20-8C30-285267D75674Q37290114-B53BAE68-4156-42C5-B9B7-FBC764DA8CECQ37336304-C7995316-4A72-4476-A7DC-E9BDD32DFC36Q37349215-27D3A3A1-0358-4A43-A370-2483368E4F19Q37384751-C8CFCAF5-29CC-4E9B-A99F-E9B05B21B6CBQ37627559-194C762B-1812-40A0-92C0-E763D6174C4BQ37698331-DFA4EBFD-E29C-4704-80C3-D7837C4613ABQ37825920-E49C1AA9-2A15-4EE6-9A76-CE17182817A4Q37878479-37C79429-6AF7-4CF2-B69A-E3B84CDF05AEQ37899279-2B9F9FD8-C4C3-4B12-A6DE-34E237E8E923
P2860
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
@ast
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
@en
type
label
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
@ast
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
@en
prefLabel
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
@ast
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
@en
P2093
P2860
P50
P1433
P1476
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
@en
P2093
Amena Ben Younes
Colette Creusy
Jacquelyn Engle
Julie Bertout
P2860
P356
10.1371/JOURNAL.PPAT.0020065
P577
2006-07-01T00:00:00Z